Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Investor Presentation (October 2006)
32 slides from Lisata Therapeutics's investor presentation, Oct 31, 2006
Slide 1: First Long-Term Autologous Adult Stem Cell Storage Bank
First Long-Term Autologous Adult Stem Cell Storage Bank First Long-Term Autologous Adult Stem Cell Storage Bank NEOI.OB
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performa
Slide 3: Over 40 million Americans suffer from chronic diseases
Over 40 million Americans suffer from Congestive Heart failure, Coronary Artery Disease, Diabetes, Osteoporosis, Rheumatoid Arthritis, and Systemic Lupus Erythomatosis All of them should have their Stem Cells banked for future therapeutic treatments!
Slide 4: NeoStem Offers Adults
NeoStem Offers Adults: • The ability to collect their stem cells through a painless non-invasive technique • The ability to keep them stored in packaging so that there can be multiple uses later in life • The ability to have Stem Cells immediately available for future therapies that they will not re
Slide 5: This is Bio-Insurance
This is Bio-Insurance Be prepared for regenerative medicine…
Slide 6: Stem Cells and Pluripotency
Stem Cell -PRIMITIVE AND THUS UNSPECIALIZED -SELF-RENEWING -CAN DIFFERENTIATE INTO CELLS WITH SPECIFIC FUNCTIONS Stem Cell -PRIMITIVE AND THUS UNSPECIALIZED -SELF-RENEWING -CAN DIFFERENTIATE INTO CELLS WITH SPECIFIC FUNCTIONS Ectoderm Ectoderm Mesoderm Mesoderm Endoderm Endoderm Cardiac Skeletal Ren
Slide 7: Embryonic Stem Cells
Embryonic Stem Cells Typically derived from 4-5 day old embryos and are a hollow microscopic ball of cells called the Blastocyst No current therapeutic uses
Slide 8: Adult Stem Cells
Adult Stem Cells An Adult Stem Cell is an undifferentiated cell found among differentiated cells in a tissue or organ The principal sources of Adult Stem Cells are: Cord Blood Bone Marrow Peripheral Blood Numerous current therapeutic uses
Slide 9: Pluripotency of mesenchymal stem cells derived from adult marrow
articles —a Pluripotency of mesenchymal stem cells derived from adult marrow Yuehua Jiang", Balkrishna N. Jahagirdar’, R. Lee Reinhardts, Robert E. Schwartz“, C. Dirk Keenel|, Xilma R. Ortiz-Gonzalez||, Morayma Reyes", Todd Lenvik*, Troy Lund’, Mark Blackstad’, Jingbo Du’, Sara Aldrich, Aaron Lisher
Slide 10: Diseases Treatable with Stem Cells
Diseases Treatable with Stem Cells TODAY • Leukemias • Lymphoma • Multiple Myeloma • Coronary Heart Disease • Radiation Sickness • Anemia • Tissue Repair & Burns FUTURE POSSIBILITIES • Spinal Cord Injuries • Stroke • Parkinson Disease • Lou Gehrig’s Disease (ALS) • Breast and Ovarian Cancer • Diabet
Slide 11: Outside the U.S.
Outside the U.S. Japan: Treated babies with cardiac malformations with Adult Stem Cells Germany, Thailand, Switzerland, Russia & India: Treated heart disease with Adult Stem Cells (Dr. Patel from the University of Pittsburg Medical Center flew overseas to treat singer Don Ho) Argentina: Treated Type
Slide 12: Companies Focused on Adult Stem Cell Therapeutics
Companies Focused on Adult Stem Cell Therapeutics Adult Stem Cells to treat Crohn’s Disease Osiris Adult Stem Cells from bone marrow to treat patients with Sickle Cell Cellerent Therapeutics Placental stem cells for wound healing Stemnion Adult Stem Cells from testes are being reprogrammed to create
Slide 13: Clinical Trials
Clinical Trials • 549 Clinical Trials using Stem Cells • 162 Clinical Trials using Autologous Stem Cells Source: www.clinicaltrials.gov
Slide 14: Acute Myocardial Infarction Trials
Acute Myocardial Infarction Trials
Slide 15: Auto Bone-Marrow Treatment for Severe Autoimmune Disease
Auto Bone-Marrow Treatment for Severe Autoimmune Disease • Fassas (J. Neurol. 2002) Rx 188 pts with MS including 99 pts 2nd progressive, 19 primary progressive, 41 relapsing forms - 34 % sustained improvement • Snowden (J. Rheumatol. 2004) All 78 pts with RA showed significant improvement, 10% remai
Slide 16: Autologous bone-marrow cells in non-healing chronic wounds
Autologous bone-marrow derived cells were used in the treatment of 3 patients with non-healing chronic wounds. ♦Complete closure and evidence of dermal rebuilding ♦Clinical and histologic evidence of reduced scarring Evangelos V. Badiavas and Vincent Falanga. Arch.Dermatol. 139:510, 2003
Slide 17: Treatment of Chronic Wounds With Bone-Marrow Derived Cells
Treatment of Chronic Wounds With Bone-Marrow Derived Cells Hernigou P et al. J Bone & Joint Surg 87A: 1430, 2005 Fracture Fracture N o n u n i o n N o n u n i o n 1 m p o s t B M S C 1 m p o s t B M S C 2 m p o s t B M S C 2 m p o s t B M S C 3 m p o s t B M S C 3 m p o s t B M S C Percutaneous Auto
Slide 18: Radiation Sickness (Hematopoietic Syndrome)
Radiation Sickness (Hematopoietic Syndrome) At 3.5 Gy 50% will die within 60 days w/o intervention Primary cause of death is infection Individuals exposed to 0.7 - 4.0 grays (Gy) will develop syndrome Rescue through Stem Cell transplant - treatment of choice Success rate very high when administered
Slide 19: Autologous = Self, Allogeneic = Non-Self
Autologous = Self Allogeneic = Non-Self • Odds of finding compatible Stem Cell donor match is 1 in 100,000 • 18% of those needing a match are able to find one from Bone Marrow Donor Registry
Slide 20: Autologous vs. Allogeneic Stem Cells
Stem Cell Infusion (Transplant) Possible None HIV, Hepatitis etc. from Donor Slower Faster Immune Recon. Slower Faster Engraftment Yes No Graft v. Host Yes No Rejection Required Not Required Tissue Matching Autologous Autologous Allogeneic Allogeneic Autologous vs. Allogeneic Stem Cells
Slide 21: NeoStem Stem Cell Collection
NeoStem • G-CSF (480 ug) Mobilization of Adult Stem Cells • Extracted using Apheresis - Non-Invasive - Done in doctor’s office - Under 3 hours • Stored in controlled rate freezer (liquid nitrogen) • Collection includes Stem Cells, Progenitor Cells, Mononuclear Cells • Stored in containers that allow
Slide 22: NeoStem Cell Processing and Storage
NeoStem Cell Processing and Storage
Slide 23: Intellectual Property
Intellectual Property NeoStem has two pending U.S. patent applications describing key aspects of our process. These applications are: 1. Elective Collection and Banking of Autologous Peripheral Blood Stem Cells. Publication Number 20040258673, Application Number 10/819,342, Priority Date April 2003
Slide 24: Intellectual Property (Cont.)
Intellectual Property (Cont.) 2. System Capable of Treating and Defining Various Disease States Using Stem Cells. Publication Number 20040265281, Application Number 10/819,398 Priority Date April 2003 • This pending application addresses the use of stored stem cells to form the basis for a data set
Slide 25: Appeal to Health Care System - Savings
~$4,000/ yr. None Post -Tx Drugs <50% Not Applicable Match Avail. Very Low With Storage Minority Avail. $300 - $500 K ~$50,000 Total Cost of Tx >$22,000 ~$6,000 Cost of Cells 90 days (avg.) 1-2 days Time to Tx Long (>30 days) Short (<5 days) Hospitalization Autologous Autologous Allogeneic Allogenei
Slide 26: Comparison of Different Sources of Adult Stem Cells
Comparison of Different Sources of Adult Stem Cells (D) Schoemans et al Bone Marrow Transplantation 38:83, 2006 (C) Zubair et al Transfusion 44:253, 2004 (B) Zeiher (Schachinger et al) J. Amer. Coll. Cardiology 44:1690, 2004 (A) Badiavas & Falanga, Arch. Derm 139:510, 2003 *Primarily Buffy Coat **Wh
Slide 27: Long-Term Viability of Stored Stem Cells
Long-Term Viability of Stored Stem Cells One study has shown no significant loss of cell viability in Stem Cells stored for up to ten years McCullough J, Clay M, Wagner JE. Cord blood stem cells. In Ball ED, Lister J, Law P, editors: Hematopoietic Stem Cell Therapy. Philadelphia: Churchill Livingsto
Slide 28: Comparables
Comparables All Numbers in Millions of Dollars All Numbers in Millions of Dollars All Numbers in Millions of Dollars (10/24/06* Market Cap/Revenue/Net Income) Comparable Public Companies (*Source Yahoo! Finance) Profit/(Loss) Sales Market Value Symbol (15.7) 44.4 191.9 (VIAC) ViaCell, Inc. (6.1) 12.
Slide 29: Potential Market and Opportunity
Potential Market and Opportunity Prevalence Disease 204,999 diagnosed new cases per year Breast Cancer 253,000 Spinal Cord Injury 20.8 million Diabetes 200,000 Sickle Cell Anemia 388,571 Multiple Sclerosis 5 million (550,000 new cases per year) Congestive Heart Failure 6 million Coronary Artery Dise
Slide 30: NeoStem Milestones
NeoStem Milestones Over the last 5 months: • Closed on just under 4 million dollars • 10:1 Reverse stock split • Sustained post split increase in stock price • Received License of California Stem Cell Bank • Signed first Collection Center Agreement • Hired a seasoned Sales and Marketing Director Ove
Slide 31: Capitalization Table October 18, 2006
28,718,129 227,204 Shares required for Convertible Promissory Notes 6,117,219 Warrants 2,895,998 Stock Options 19,477,708 Common Stock Shares Capitalization Table October 18, 2006 NeoStem, Inc. Comp Table
Slide 32: Management/Directors/Senior Staff
Management/Directors/Senior Staff • Robin Smith, M.D., MBA, NeoStem Chairman of the Board and CEO. Chairman of Advisory Board for China Biopharmaceuticals (OTC BB: CHBP), Chairman of NYU-Hospital for Joint Diseases • Mark Weinreb, NeoStem Director and President. Former Owner, Bio Health Laboratories